Ann: FOURTH SITE IN HEPATITIS C CLINICAL TRIAL, page-6

I contacted the company last week. They will not be reporting Patient 7 & 8 dosing. They will only report on a cohort basis. Probably 2-3 months of more share price manipulation until some sort of expectation starts, unless the end of the silent period allows them to talk about other things.

So far 2015 has seen the trial proceed at glacial speed, a uniquely botched IPO and a 50% fall in the share price. No what we expected by a long shot.